1. Structural modification of the propyl linker of cjoc42 in combination with sulfonate ester and triazole replacements for enhanced gankyrin binding and anti-proliferative activity.
- Author
-
Chavan T, Kanabar D, Patel K, Laflamme TM, Riyazi M, Spratt DE, and Muth A
- Subjects
- Humans, Structure-Activity Relationship, Molecular Structure, Drug Screening Assays, Antitumor, Sulfonic Acids chemistry, Sulfonic Acids pharmacology, Sulfonic Acids antagonists & inhibitors, Cell Line, Tumor, Esters chemistry, Esters pharmacology, Esters chemical synthesis, Proteasome Endopeptidase Complex metabolism, Proteasome Endopeptidase Complex chemistry, Dose-Response Relationship, Drug, Liver Neoplasms drug therapy, Liver Neoplasms pathology, Liver Neoplasms metabolism, Benzenesulfonates, Triazoles chemistry, Triazoles pharmacology, Triazoles chemical synthesis, Cell Proliferation drug effects, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents chemical synthesis, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins antagonists & inhibitors
- Abstract
Liver cancer is a complex disease that involves various oncoproteins and the inactivation of tumor suppressor proteins (TSPs). Gankyrin is one such oncoprotein, first identified in human hepatocellular carcinoma, that is known to inactivate multiple TSPs, leading to proliferation and metastasis of tumor cells. Despite this, there has been limited development of small molecule gankyrin binders for the treatment of liver cancer. In this study, we are reporting the structure-based design of gankyrin-binding small molecules which inhibit the proliferation of HuH6 and HepG2 cells while also increasing the levels of certain TSPs, such as Rb and p53. Interestingly the first molecule to exhibit inhibition by 3D structure stabilization is seen. These results suggest a possible mechanism for small-molecule inhibition of gankyrin and demonstrate that gankyrin is a viable therapeutic target for the treatment of liver cancer., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF